January 17, 2007
German gov’t deals blow to Sanofi-Aventis’ Acomplia
Sanofi-Aventis said it intends to contest in court the decision by the German health ministry to classify anti-obesity drug Acomplia as a non-reimbursable drug.
The ministry recommendation was published in the Official Journal of the Government, prompting an immediate response by the drug maker.
“Sanofi-Aventis considers the proposed reimbursement classification of Acomplia as unjustified given the profile of the drug,” the firm said in a statement.
Sanofi has argued that, since it helps lower a person's risk for developing diabetes and heart disease in addition to helping with weight loss, rimonabant should be covered under the state health insurance program.